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BEL-1 is an acquired class A extended-spectrum -lactamase (ESBL) found in Pseudomonas aeruginosa clinical isolates from
Belgium which is divergent from other ESBLs (maximum identity of 54% with GES-type enzymes). This enzyme is efﬁciently
inhibited by clavulanate, imipenem, and moxalactam. Crystals of BEL-1 were obtained at pH 5.6, and the structure of native
BEL-1 was determined from orthorhombic and monoclinic crystal forms at 1.60-Å and 1.48-Å resolution, respectively. By soak-
ing native BEL-1 crystals, complexes with imipenem (monoclinic form, 1.79-Å resolution) and moxalactam (orthorhombic form,
1.85-Å resolution) were also obtained. In the acyl-enzyme complexes, imipenem and moxalactam differ by the position of the
-substituent and of the carbonyl oxygen (in or out of the oxyanion hole). More surprisingly, the-loop, which includes the
catalytically relevant residue Glu166, was found in different conformations in the various subunits, resulting in the Glu166 side
chain being rotated out of the active site or even in displacement of its C atom up to approximately 10 Å. A BEL-1 variant show-
ing the single Leu162Phe substitution (BEL-2) confers a higher level of resistance to CAZ, CTX, and FEP and shows signiﬁcantly
lower Km values than BEL-1, especially with oxyiminocephalosporins. BEL-1 Leu162 is located at the beginning of the-loop
and is surrounded by Phe72, Leu139, and Leu148 (contact distances, 3.5 to 3.9 Å). This small hydrophobic cavity could not rea-
sonably accommodate the bulkier Phe162 found in BEL-2 without altering neighboring residues or the-loop itself, thus likely
causing an important alteration of the enzyme kinetic properties.
Among Gram-negative bacteria, the production of one or sev-eral -lactamase(s) represents the major mechanism of resis-
tance to -lactam antibiotics (1). Extended-spectrum -lactama-
ses (ESBLs) are enzymes which confer resistance not only to
penicillins and narrow-spectrum cephalosporins but also to ex-
panded-spectrum cephalosporins, such as cefotaxime, ceftriax-
one, ceftazidime, and cefepime. ESBL production in clinically
relevant opportunistic pathogens, such as Enterobacteriaceae,
Pseudomonas aeruginosa, and Acinetobacter baumannii (2), is now
relatively common, and such isolates are globally spread, repre-
senting an important issue for successful antimicrobial chemo-
therapy (1, 2).
Besides the TEM- and SHV-derived variants, which acquired
ESBL properties by means of speciﬁc mutations, an increasing
number of -lactamases have been reported which showed native
ESBL properties, such as the widespread CTX-M-type enzymes,
but also the less frequently observed PER-, VEB-, and GES-type
enzymes. More recently, a novel and divergent ESBL was identi-
ﬁed in a Pseudomonas aeruginosa clinical isolate from Belgium
that shared at most 50% identity with GES-type enzymes and
showed interesting biochemical properties, such as inhibition by
moxalactam and low afﬁnity for ceftazidime, as well as relatively
low turnover rates for most substrates (3). Even more recently, a
variant exhibiting a unique substitution (Leu162Phe in BEL-2)
was identiﬁed and showed signiﬁcantly different activity on cefta-
zidime, resulting from much lower Km values for expanded-spec-
trum cephalosporins (4).
In this work, we describe the crystal structure of the native
BEL-1 ESBL and of its acyl-enzyme complexeswith imipenemand
moxalactam, the latter representing the ﬁrst observation of this
substrate in a class A -lactamase, providing insight into the spe-
ciﬁc structural features that could account for the enzyme prop-
erties and the importance of position 162 (where the single sub-
stitution occurring in BEL-2 is observed) in the binding and
recognition of -lactam substrates.
MATERIALS AND METHODS
We use the term “native” BEL-1, although most of the subunits contain a
citrate molecule in the active site, to make a distinction from the imi-
penem- and moxalactam-bound forms of the enzyme. The nomenclature
of BEL-1 used here refers to the residue numbering in the PDB coordi-
nates and follows the BEL-1 sequence [UniProt Q3SAW3_PSEAI]. When
the consensus numbering of class A -lactamases [ABL numbering] is
used, the position of corresponding BEL-1 residues is provided.
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Puriﬁcation of BEL-1. A near-homogeneity BEL-1 enzyme prepara-
tion was puriﬁed from a 2-liter culture of Escherichia coli BL21(DE3)/
pET-BEL-1 grown for 24 h in autoinducing medium ZYP-5052. The ex-
pression plasmid pET-BEL-1 was obtained by cloning the blaBEL-1 open
reading frame (ORF), ampliﬁed by PCR, into the NdeI and BamHI clon-
ing sites of pET-9a plasmid, as previously described (4). The culture was
centrifuged (10,000  g, 10°C, 30 min), and the clariﬁed supernatant
was concentrated using an Amicon YM30 membrane (Amicon model
2000 concentrator; Millipore Corp., Carlsbad, CA) and desalted using a
HiPrep desalting column (GE Healthcare, Uppsala, Sweden) against 30
mM morpholineethanesulfonic acid (MES) buffer, pH 6.2 (buffer M).
The resulting sample was loaded on an XK 16/20 column packed with 25
ml of CM Sepharose FF (GE Healthcare) equilibrated with buffer M and
the proteins eluted using a linearNaCl gradient (0 to 0.3M in 150ml). The
-lactamase-containing fractions were pooled, desalted as before in buf-
fer M, and loaded on a Resource S column (column volume, 1 ml; GE
Healthcare). Elution was achieved with a linear NaCl gradient in bufferM
(0 to 1 M in 20 ml). Resulting fractions were then concentrated to 10
mg/ml in buffer M containing 0.16 M NaCl using Amicon Ultra ultraﬁl-
tration devices (10-kDa-molecular-mass cutoff;Millipore, Bedford,MA).
This protocol yielded 10 mg of 98% pure BEL-1 enzyme per liter of
culture. Electrospray ionization mass spectrometry (ESI-MS) analysis,
performed as previously described (41), conﬁrmed the authenticity of the
BEL-1 preparation, with an excellent agreement between the observed
mass (28,691.0) and the theoretical value (28,688.5; after the removal of a
20-amino-acid signal peptide). A higher-mass species was also observed
(28,873.0) which likely corresponds to an alternate cleavage of the N-ter-
minal signal sequence occurring between residues 18 and 19 (theoretical
mass, 28,887.7).
Enzyme kinetics and thermal unfolding experiments. The kinetic
parameters for the inactivation of BEL-1 bymoxalactamwere determined
using the reporter substratemethod as previously described (42). The rate
of inactivation (k) of BEL-1 (ﬁnal concentration, 1.2 nM)was determined
in the presence of various concentrations of moxalactam (ﬁnal concen-
tration, 20 to 80 M) and 220 M cephalothin (reporter substrate) in 50
mM HEPES (pH 7.5) buffer. Nonlinear regression analysis of the depen-
dence of k over [moxalactam] was performed using Sigma Plot and the
following equation: k3 k2 ⁄K* I, where [I] is the moxalactam
concentration and K* is equal to KM
S  ⁄KM
S  SK; KM
S is the Km value
of the reporter substrate; K is equal to k1/k1. The conformational sta-
bilities of BEL-1 and BEL-2 (puriﬁed as previously described [4]) were
compared using thermal unfolding experiments by monitoring the
far-UV circular dichroism (CD) signal of a 20 M enzyme solution in 50
mM HEPES (pH 7.5) buffer using a Jasco J-815 spectropolarimeter. The
protein samples were heated from 20 to 90°C at a rate of 0.55°C/min, and
data were interpreted as previously described (43). Under these condi-
tions, unfolding of the -lactamases was irreversible.
Crystallization of BEL-1. Crystallization trials were performed using
the sitting-drop method (96-well CrystalEX plates; Corning) (5) and the
commercially available Crystal Screen I and II (Hampton Research, Aliso
Viejo, CA). Drops consisting of 2l protein solution (10mg/ml) and 2l
reservoir solutionwere equilibrated at room temperature (20°C) against a
100-l reservoir volume. Small, needle-shaped crystals appeared in 3
weeks with Crystal Screen I condition 40 (0.1 M sodium citrate tribasic
dihydrate, pH 5.6, 20% [wt/vol] polyethylene glycol [PEG] 4000, 20%
[vol/vol] 2-propanol), which provided a basis for further optimization
of the crystallization conditions. Using 24-well sitting-drop plates
(Cryschem plate; Hampton Research), protein drops with variable pro-
tein/precipitant volume ratios (1:1 and 1:2) were equilibrated over a 700-
or 800-l reservoir volume. Protein concentration ranged from 5.2 to 10
mg/ml, PEG 4000 concentration from 5 to 20%, wt/vol, and 1-propanol,
2-propanol, 2-butanol, or methyl-pentanediol (MPD) concentrations
from 12 to 25%, vol/vol. Crystals suitable for diffraction were obtained in
drops prepared bymixing 4l protein solution (5.2mg/ml) with 2l two
different precipitant solutions. The one composed of 0.1 M sodium ci-
trate, pH 5.6, 15% (wt/vol) PEG 4000, and 15% (vol/vol) 2-propanol,
equilibrated over an 800-l reservoir volume (solution A), provided
orthorhombic crystals in space group P21212. Monoclinic P21 crystals
were obtained from a precipitant solution containing 0.1 M sodium ci-
trate, pH 5.6, 20% (wt/vol) PEG 4600, and 20% (vol/vol) MPD, equili-
brated over an 800-l reservoir volume (solution B).
Crystals of the adducts with imipenemandmoxalactamwere obtained
by soaking experiments (30- to 60-min soaking times, respectively) using
1 to 2 mM ﬁnal substrate concentrations (resuspended in precipitant
solution) in the crystal drop in both cases. The BEL-1–imipenem complex
was obtained in themonoclinic form, while the BEL-1–moxalactam com-
plex was obtained in the orthorhombic form (Table 1).
Data collection and processing. Before data collection, all crystals
were transferred to a cryoprotectant solution (30%, wt/vol, PEG-4000/
4600, 15%, vol/vol, 2-propanol, 20%, vol/vol, MPD, and 0.1 M sodium
citrate, pH 5.6) and ﬂash frozen in liquid nitrogen. Diffraction data on the
orthorhombic crystal of the native enzyme were collected (100 K; wave-
length, 0.983 Å;	
, 0.5°) at the European Synchrotron Radiation Facility
(ESRF) on beamline ID14-1, equipped with an ADSC Quantum 210R
detector. Data collection on the monoclinic crystal of the native enzyme
and the complex with imipenem were carried out at the ESRF beamline
ID29 (100 K; wavelength, 0.976 Å;	
 [rotation angle for data collection],
0.5°) equipped with a Pilatus 6M detector. Diffraction data on BEL-1 in
complex with moxalactam were collected (100 K; wavelength, 0.920 Å;
	
, 0.2°) at the Diamond Light Source (DLS) beamline I04-1 equipped
with a Pilatus 2M detector. Data were processed using the programMOS-
FLM (6) and scaled with SCALA (7) from the CCP4 suite (8). Data col-
lection parameters and data reduction statistics are reported in Table 1.
Structure determination and reﬁnement. The BEL-1 structure was
obtained bymolecular replacement using the structure of the class A ESBL
Toho-1 (44% identity with BEL-1) as a search model (PDB code 1IYS;
water molecules and ions were omitted) (9). The program MOLREP (10)
provided an evident solution for the positioning of the two and four
BEL-1 subunits found in the asymmetric unit of the orthorhombic and
monoclinic crystal forms, respectively. Isotropic reﬁnement of the four
structures was carried out with the program REFMAC5 (11) from the
CCP4 suite. Between reﬁnement cycles, the model was subjected to man-
ual rebuilding usingCoot (12). Upon completion of the proteinmodels of
the native enzyme, inspection of the Fourier difference map clearly dem-
onstrated the presence of citrate anions in both the enzyme subunits in the
orthorhombic form and in three out of the four subunits in the mono-
clinic form. The imipenem and moxalactam inhibitors are bound in all
BEL-1 subunits.
Water molecules were added using the standard procedure within the
ARP/wARP suite (13). In the last cycle of reﬁnement, hydrogen atoms
have been added in calculated positions, contributing to the Fc calcula-
tion. The stereochemical quality of the reﬁned model was assessed using
the program PROCHECK (14) and Coot. Reﬁnement statistics are re-
ported in Table 1. The ligand placement was checked in the ﬁnal models
through the calculation of the omit maps and validated during the depo-
sition in the Protein Data Bank. Figures were prepared using the molec-
ular graphics software CCP4mg (15).
Accession number(s). Coordinates and structure factors of native
BEL-1 and its acyl-enzyme complexes with imipenem and moxalactam
have been deposited into the Protein Data Bank under codes 5EOE
(BEL-1 orthorhombic form), 5EOO (BEL-1 monoclinic form), 5EPH
(BEL-1–imipenem complex), and 5EUA (BEL-1–moxalactam complex).
RESULTS AND DISCUSSION
BEL-1 overall fold. BEL-1 crystals display a high propensity to
polymorphism. The native enzyme was indeed obtained in both
orthorhombic (P21212 space group) and monoclinic (P21 space
group) forms. Similarly, the imipenem and moxalactam acyl-en-
zyme complexes crystallized in the monoclinic P21 and ortho-
rhombic P212121 space groups, respectively (Table 1). In the
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orthorhombic formP21212, the ﬁnalmodel consisted of two com-
plete, independent BEL-1 molecules related by almost exact non-
crystallographic 2-fold symmetry. The asymmetric unit of the
monoclinic crystals consists of two of such dimers.However, anal-
ysis of the protein interface by the PISA software (http://www.ebi
.ac.uk/msd-srv/prot_int/pistart.html) indicates that the dimeric
arrangement observed in the crystals does not represent a stable
quaternary structure and is not maintained in solution. Similar
unstable dimeric arrangements also have been observed in the
crystal structures of other class A enzymes, like PER-2 (PDB code
4D2O) (16) and SED-1 (PDB code 3BFE) (L. Pernot et al., unpub-
lished data).
The four BEL-1 crystal structures presented here are deter-
mined at high resolution, and the electron density is of very good
quality, allowing the tracing of the chains from Asp21 (two N-ter-
minal residues, Gln19-Ala20, of the mature protein are missing)
TABLE 1 Data collection, reﬁnement and ligand validation statistics
Parameter
Value(s) for BEL-1 type:
Native
(orthorhombic form)
Native
(monoclinic form) Imipenem complex Moxalactam complex
PDB code 5EOE 5EOO 5EPH 5EUA
X-ray source ESRF ID14-1 ESRF ID29 ESRF ID29 DLS I04-1
Wavelength (Å) 0.934 0.976 0.976 0.920
Data collection temp (K) 100 100 100 100
Space group (no.) P21212 (18) P21 (4) P21 (4) P212121 (19)
Cell dimensions (Å) a 100.27,
b 120.92, c 53.41
a 54.84, b 94.69,
c 103.68,   92.64
a 53.98, b 95.86,
c 103.42,   91.97
a 70.53, b 80.91,
c 86.64
Subunit/asymmetric unit (no.) 2 4 4 2
Matthews coefﬁcient (Å3 Da1) 2.66 2.11 2.10 2.20
Solvent content (%) 53.87 47.79 41.46 44.21
Resolution limita (Å) 29.25–1.60 (1.69–1.60) 51.78–1.48 (1.56–1.48) 51.68–1.79 (1.89–1.79) 33.58–1.85 (1.95–1.85)
No. of reﬂectionsa
Measured 1,177,930 (169,097) 389,425 (57,732) 223,222 (33,531) 264,536 (40,492)
Unique 86,406 (12,467) 154,141 (22,851) 91,836 (13,854) 42,901 (6,182)
Completenessa (%) 99.9 (99.9) 88.0 (89.7) 93.2 (96.4) 99.7 (100.0)
Rmerge
a,b (%) 7.6 (39.7) 14.9 (38.0) 8.4 (38.8) 8.0 (42.7)
Multiplicitya 13.6 (13.6) 2.5 (2.5) 2.4 (2.4) 6.2 (6.5)
I/(I)a 25.0 (6.9) 4.3 (2.2) 7.5 (2.7) 12.6 (3.8)
Wilson B factor (Å2) 14.11 12.68 16.44 19.68
Rcryst
a,b (%) 14.2 (18.4) 16.3 (23.1) 16.4 (23.1) 16.6 (22.9)
Rfree
a,b (%) 16.7 (22.1) 18.7 (24.5) 20.2 (29.5) 21.5 (26.7)
No. of:
Protein atoms 4009 7951 7862 3936
Ligand atoms 86 75 93 104
Water molecules 800 944 685 305
Avg B factor (Å2) 14.59 15.98 20.74 27.59
RMSD
Bond length (Å) 0.013 0.013 0.017 0.015
Bond angle (°) 1.677 1.646 1.767 1.697
Ramachandran plot residues (%)
Most favored regions 98.7 98.9 98.7 98.8
Additionally allowed regions 1.3 1.1 1.3 1.2
Disallowed regions 0.0 0.0 0.0 0.0
Ligand
LLDFc 1.02, 4.06, 0.10, 4.88f 0.04, 2.26g
RSRd 0.13, 0.11, 0.10, 0.12f 0.12, 0.21g
RSCCe 0.95, 0.96, 0.96, 0.94f 0.91, 0.79g
a Data in parentheses refer to results for the highest-resolution shell.
b Rmerge hi|Ii,h Ih|/hiIi,h 100. Rcryst(Rfree) h||Fh,obs| |Fh,calc|/h||Fh,obs| 100.
c LLDF, local ligand density ﬁt as reported by PDB validation.
d RSR, real space R value as reported by PDB validation.
e RSCC, real space density correlation coefﬁcient as reported by PDB validation.
f Values for ligand in chains A, B, C, and D.
g Values for ligand in chains A and B.
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to His283, except in some portions of the loop (residues 150 to
172) and the C termini of a few subunits (see “Acyl-enzyme com-
plexes of BEL-1,” below).
The tertiary structure of BEL-1 displays the characteristic fold
of class A-lactamases (17) (Fig. 1A), consisting of a ﬁve-stranded
antiparallel -sheet (2, 1, 5, 4, and 3) sandwiched on one
side by the N- and C-terminal helices 1 and 9 and on the other
by helices 2 to 8, as shown in Fig. 1A. The active site is deﬁned
by the interface between the -sheet and the large 2-8 domain.
Helix 6 is linked to helix 7 by the large -loop that covers
the active site. Another large loop (BEL-1 residues 79 to 98) link-
ing 2 to 3 constitutes part of the active-site channel. The initial
turn of helix 2 contains the active-site motif 1 (S70xxK), bearing
the catalytically active serine residue (BEL-1 residues 62 to 65).
All of the subunits in all crystal structures display the same
conformation except, as already mentioned, for residues in some
-loops that are not visible due to the high ﬂexibility of this re-
gion. No signiﬁcant structural differences could be observed be-
tween independent enzyme molecules found in the different crys-
tal asymmetric units. Their rootmean square deviations (RMSDs)
calculated on C atoms range between 0.26 Å and 0.66 Å.
BEL-1 active site and interaction with citrate. Figure 1B
shows the electron density 2Fo-Fc map in the BEL-1 (orthorhom-
bic form) active site where a citrate molecule from the crystalliza-
tion buffer is bound. Besides motif 1 (S70xxK; BEL-1 residues
Ser62-Thr63-Phe64-Lys65), the electron density of the conserved
motifs 2 (S130xN; BEL-1 residues Ser123-Asp124-Asn125) and 3
(K234xG; BEL-1 residues Lys227-Thr228-Gly229) is also shown.
Other residues, including the catalytically important Glu166, are
located in the omega loop and constitute the ﬂoor of the active site
FIG1 (A)Overall fold of BEL-1. The polypeptide chain is rainbow colored, starting from theN terminus (blue) to theC terminus (red). The secondary-structure
elements are labeled. (B) The four conservedmotifs in BEL-1 are shown as sticks.Motif 1 (green) is located at the beginning of helix-2, motif 2 (purple) is located
in the loop between 4 and 5, motif 3 (brown) is on 3, and motif 4 (cyan) is on the-loop. The citrate molecule is shown as yellow sticks. The Fo-Fc Fourier
differencemap, corresponding to the fourmotifs and citrate, is shown as a wire contoured at 1.2 in colors related tomotifs 1 to 4 (pale-green, pink, pale brown,
and cyan, respectively), while that of citrate is colored blue. (C) The H-bonding scheme involving the citrate atoms is shown together with the water molecule
involved in the deacylation of the reacted substrate (Wat). This binding of the citrate anion was observed in both subunits of the orthorhombic BEL-1 crystals.
(D) Alternate binding of the citrate anion and relative interaction network, as observed in subunits A andCof themonoclinic BEL-1 crystals (in subunit B, citrate
wasmodeled in two alternative conformations, omitted for clarity, whereas in subunitD itwas not detected). Arg236was observed in two alternative orientations,
but only the one involved in citrate binding is shown here for clarity.
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(BEL-1 residues Glu159, Pro160, Thr161, Leu162, and Asn163)
(Fig. 1B). These residues have been shown to be involved in sub-
strate recognition in class A -lactamases (18). Figure 1C shows
the H-bonding network involving the citrate anion and the resi-
dues in the BEL-1 active site. The citrate oxygen atoms (in the
orthorhombic form) interact with the side chains of catalytically
relevant residues of the three conserved motifs and with the side
chains of BEL-1 residues Thr209, Ser230, andArg236 (in themon-
oclinic form only). This positively charged area in the active-site
cavity is important to accommodate the carboxylated group of
-lactamase substrates, as it has been shown in the structures of
various class A -lactamase acyl-enzyme complexes (e.g., TEM-1
and imipenem (19).
The binding of polycarboxylates is not uncommon for -lac-
tamases, as citrate has already been observed bound to TEM-72
(20) and to KPC-2 (21), to the class C CMY-2 (PDB entry 1ZC2)
(C. Bauvois et al., unpublished data), to a -lactamase/D-Ala-D-
Ala-carboxypeptidase fromYersinia pestis (PDB: 3RJU) (Y. Kim et
al., unpublished data), and even to the metallo--lactamase BcII
(PDB code 1MQO) (I. Garcia-Saez et al., unpublished data). Tar-
trate has been found bound to OXA-46 (22). Interestingly, in the
last example, the tartrate binding can be observed only when the
conserved Lys75 (motif 1) is not carbamylated. This ﬁnding sup-
ports the hypothesized preferential inhibition of class A -lacta-
mases, rather than other serine--lactamases, by polycarboxylate
molecules. The possibility of inhibiting -lactamases by using
polycarboxylates has been explored recently (23).
Citrate anions are found bound in both independent subunits
of the orthorhombic formof BEL-1, while citrate is present only in
three out of four BEL-1 subunits of the monoclinic form, where it
adopts a different orientation that displaces the Wat molecule H
bonded to Glu166 and Asn170 (BEL-1 residues 159 and 163) in
the orthorhombic form.
TheN atoms of Lys73 (BEL-1 residue 65), inmotif 1, establish
a hydrogen bond with the catalytic Ser70 (BEL-1 residue 62) on
the same motif, with Ser130 and Asn132 of motif 2 (BEL-1 residues
123 and 125) and Glu166 on the-loop (not shown in Fig. 1C).
The two residues Glu166 and Asn170 establish a hydrogen
bonding network with Wat (Fig. 1C), the nucleophile in the sec-
ond step of the catalyzed reaction (24). The other highly conserved
water molecule, which usually occupies the oxyanion hole be-
tween helix 2 and strand 3, bridging Ser70 and Thr235, is not
present in this BEL-1 structure, being displaced by the carboxylate
group of citrate. Upon binding, the citrate anions displace at least
four water molecules seen in the active site of the unbound sub-
unit.
Acyl-enzyme complexes of BEL-1. The structure of the acyl-
enzyme form of BEL-1 resulting from binding of imipenem and
moxalactam, two -lactam compounds which efﬁciently inacti-
vatedBEL-1, have been obtained at a resolution of 1.79 and 1.85Å,
respectively (Table 1). In both adducts, the hydrolyzed formof the
inhibitor could be modeled in all subunits.
In the BEL-1–imipenem complex, obtained in the monoclinic
crystal form (Fig. 2), the inhibitor adopts similar conformations in
all subunits except for the imino-methylamino-ethyl chain, which
extends out from the cavity and is disordered. Beyond the covalent
bond to Ser70 (BEL-1 Ser62), the imipenem carboxylate group is
H bonded to Thr235 (BEL-1 Thr228), although this interaction
involves a single oxygen atom (O31) of the substrate carboxylate
group, and the 6--hydroxyethyl substituent is H bonded to
Asn132 (BEL-1 Asn125). A comparison with the TEM-1–imi-
penem acyl-enzyme complex highlights some differences (19)
(Fig. 2D). In TEM-1, the imipenem carboxylate is located close to
and interacts with Ser235 and Arg244 residues, but sits approxi-
mately 2.8 Å away from that position in the BEL-1 complex and
only interacts with the Thr235 (228) side chain hydroxyl group
and backbone carbonyl. Interestingly, the carbonyl oxygen of the
TEM-1-bound imipenem is located in the oxyanion hole of the
enzyme active site, while it is located outside the BEL-1 complex.
Indeed, the O6 carbonyl oxygen does not occupy the oxyanion
hole but is H bonded to Lys73 (BEL-1 Lys65) in a conformation
that would not allow inhibitor hydrolysis. In addition, the C6--
hydroxyethyl group also shows a different orientation in both en-
zymes, resulting from the rotation of C5-C6 of the molecule. In
the TEM-1 complex, the deacylation water molecule, although
displaced by the hydroxyl group of the C6 imipenem substituent,
is visible and interacts with Glu166, Asn170, and the hydroxyl
oxygen of the substrate C6 substituent. In the BEL-1 complex, this
water molecule could not be observed, and the hydroxyl group of
this C6 substituent points towards the active site. The binding of
imipenem in BEL-1 seems to modify the H-bonding pattern link-
ing the active site with residues in the-loop, causing disorder in
the loop that is fully visible only in subunit D, while 2 to 10 resi-
dues are missing from the other subunits (missing residues are
Thr164 and Asn165 in subunit A, Glu159 to Asn165 in subunit B,
andThr164 to Pro167 in subunit C). Figure 2B shows thatGlu166,
located at the-loop, is H bonded to carbonyl O of Cys69 (2.9 Å),
suggesting its protonated state. Asn170 has moved away from the
cavity, and the water molecule bridging the two residues in the
native form of the enzyme (Fig. 1D) disappeared. The -loop in
the D subunit has an open conformation, unobserved so far in
class A enzymes, pointing away from the active-site crevice as
shown in Fig. 2C. The open conformation of the-loop, although
not fully traceable, is also seen in the unbound subunit D of the
BEL-1 native monoclinic form. The Glu166-Wat-Asn170-H-
bonded triad shown in Fig. 1C is disrupted in all subunits of imi-
penem-bound BEL-1.
The two independent subunits of the moxalactam-bound
complex of BEL-1 (orthorhombic form P212121) are identical ex-
cept in the -loop region, which is observed in subunit A but
highly disordered in subunit B (missing residues are Glu159
to Asp169). Moxalactam, bearing a C7--methoxy substituent
granting the compound some level of stability to -lactamase-
mediated hydrolysis, is covalently bound to the Ser62 side chain in
both subunits, but the 1-methyl-5-thiotetrazole group of moxa-
lactam is not visible and appears to have been cleaved upon rear-
rangement of moxalactam electronic structure due to the acyla-
tion reaction leading to a 3=-methylene species (25), as already
observed in reported AmpC-moxalactam complex structures (26,
27) (Fig. 3). Although moxalactam is surely bound to subunit B
(the open -lactam ring and the oxa-azaciclo-carboxyl moiety are
clearly visible in the electron density map), less deﬁned electron
density was observed for the carboxy-hydroxyphenyl portion of
the molecule, preventing the moxalactam molecule from being
fully modeled in this subunit. For this reason, the following de-
scription refers to moxalactam bound in BEL-1 subunit A.
The hydrolyzed moxalactam molecule interacts with many
conserved residues of the site, as reported in Fig. 3B. The C8 car-
bonyl oxygen is found in the oxyanion hole formed by the back-
boneN atoms of Ser70 (BEL-1 Ser62) and Ser237 (BEL-1 Ser230).
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The C7 -methoxy oxygen makes an H bond to Lys73, while the
C4 carboxylate group is H bonded (with both oxygen atoms) to
the side chains of residues Lys234 and Thr235 (Fig. 3B).
In contrast to the BEL-1–imipenem complex, in which the
Glu166 residue was observed in a signiﬁcantly different position
compared to that in the structure of the native protein, residues
Asn159 and Glu166 were observed in a native-like conformation,
and the deacylated water was located at 3.2 ( 0.1) Å from the
moxalactam C28 atom of the scissile Ser70-moxalactam bond.
The inactivation of BEL-1was investigated by kineticmethods,
which conﬁrmed that BEL-1 acylation bymoxalactam is relatively
fast (k2/K, 1.9 10
3 M1 · s1) but that deacylation takes place
slowly (k3, 3.2  10
3 s1). The slow deacylation of a -lacta-
mase inhibitor has been observed for avibactambound to the class
A CTX-M-15 enzyme. In this case, it has been demonstrated that
deacylation occurs by a recyclization mechanism and not by the
intervention of the deacylating water (28–30). The atomic-reso-
lution crystal structure of the CTX-M-15–avibactam complex
(29) shows a protonated Glu166 carboxylate oxygen forming a
short low-barrierHbond to the deacylatingwater that acts as anH
FIG 2 (A) Electron density from the ﬁnal omitmap corresponding to imipenem covalently bound to Ser62 is shown as a blue wire contoured at 2.7. The BEL-1
residues corresponding to the four motifs described in the legend to Fig. 1 are shown as sticks following the same color code. The traced portion of the open,
disordered -loop is also shown. (B) H bonds involving imipenem within the BEL-1 active site. The residue colors follow the above-described scheme. The
Glu159 (ABLGlu166) side chain is nowHbonded to the carbonyl oxygen of Cys61 (ABLCys68), and Asn163 (ABLAsn170) hasmoved away from the active site.
(C) The two observed conformations of the-loop shown by superimposing the citrate-bound orthorhombic form of BEL-1 (closed conformation; light blue
ribbon) with subunit D of the unboundmonoclinic BEL-1 form (green ribbon;-loop partially traced) and with the imipenem-bound BEL-1 (magenta ribbon;
complete open conformation). The imipenem molecule is shown as yellow sticks to locate the BEL-1 active site. (D) Comparison of the active site of the
imipenem-bound structures of BEL-1 (blue) and TEM-1 (orange), showing the different position and orientation of the imipenem molecule in both enzymes.
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bond acceptor. In such an arrangement, the lone pair of that water
is not productively oriented toward the scissile acyl carbon. At the
resolution of the present BEL-1–moxalactam structure, hydrogen
atoms cannot be observed. However, Glu166 establishes a very
shortH bond to the deacylating water (2.4 Å) (Fig. 3B), suggesting
the presence of a low-barrier H bond, similar to that observed in
the CTX-M-15–avibactam complex and the same nonproductive
orientation of the water lone pairs, possibly explaining the kinetic
data on moxalactam.
Structural comparison of native BEL-1 and its complexes
with other class A -lactamases. The comparison of the BEL-1
crystal structure with other class A -lactamases clearly demon-
strates the high structural conservation that characterizes the en-
zymes belonging to this class despite low sequence identity (rang-
ing from 26% to 54% for PER-1 and GES-1; the sequence
alignments are reported in Fig. 4).
Least-squares superimposition of the BEL-1 structure with
representatives of TEM, SHV, CTX-M, PER, SED, PenP, KPC,
andGES subfamilies yields RMSDs onC ranging between 0.96 Å
(GES) and 1.75Å (PER-1). The largest structural deviations occur
in the two terminal helices (1 and 9), in the short loop between
strands 1 and 2, in helix 8 and the loop connecting this helix
with strand 3, and in the short loop between 4 and 5. The
three conservedmotifs overlap almost perfectly in all of the crystal
structures of the above-described class A enzymes.
Surprisingly, a disulﬁde bond between Cys69 and Cys238
(BEL-1 residues 61 and 231) is clearly visible in the BEL-1 crystal
structure, as indicated by the continuous electron density between
the sulfur atoms of the two cysteine residues. This disulﬁde bond
was previously observed in GES-type -lactamases and in carbap-
enemases, such as SME-1, NMC-A, and KPC-type enzymes (21,
31–33). The superimposition of disulﬁde-containing carbapen-
emases (including GES-2, SME-1, NMC-A, and KPC-2) and a
number of penicillinases and cephalosporinases which do not
have a similar disulﬁde bridge (such as TEM-1, in which a disul-
ﬁde bridge is found between residues 77 and 123 instead) shows
that in the disulﬁde-containing enzymes, helix 2 is positioned
slightly closer to the -domain than in the other enzymes. This
highly conserved bond in the active site is considered a deﬁning
difference between carbapenemases and penicillinases in class A
enzymes (34), and until now, its presence has been observed in all
subtypes of class A -lactamases which successfully evolved car-
bapenemase activity (such as in NMC-A and some GES-type en-
zymes). It is therefore surprising that this disulﬁde bond is present
in BEL-1, which is unable to hydrolyze carbapenem substrates and
is instead readily inactivated by imipenem (3) and moxalactam.
A structural feature conserved in class A -lactamases is the cis
conformation of the Glu166-Pro167 peptide bond. This conﬁgu-
ration is stabilized by two hydrogen bonds between Glu166 and
Asn136 favoring the conﬁguration of the -loop and the correct
placement of Glu166 and Asn170. These two residues establish an
H-bonding network involving their side chains and the catalytic
water molecule for the deacylation step and contribute to its acti-
vation (Fig. 1D). The relevance of the H-bonding network in the
catalysis and inhibition mechanism of class A enzymes has been
demonstrated (29, 35). The arrangement of the -loop is also
stabilized by a salt bridge between Arg164 and Asp179 (BEL-1
residues 157 and 172). These four residues (Arg164, Glu166,
Pro167, and Asp179) are conserved in all sequences of class A
-lactamases considered in the present alignment (Fig. 4) except
for the PER-1 enzyme, in which residues Arg164, Pro167, and
Asp179 are replaced by Ala164, Ala167, and Asn179, respectively.
The crystal structure of PER-1 clearly shows that the Glu166-
Ala167 peptide bond adopts a trans-conformation (36). More-
over, the replacement of the conserved Arg164 (BEL-1 residue
157) by an alanine in PER-1 results in the loss of the salt bridge
interaction that contributes to stabilize this loop in other class A
FIG 3 (A) Electron density from the ﬁnal omit map corresponding to moxa-
lactam covalently bound to Ser62 is shown as a blue wire contoured at 3. The
BEL-1 residues corresponding to the fourmotifs described in the legend to Fig.
1 are shown as sticks by following the same color code. (B) H bonds involving
moxalactam within the BEL-1 active site. The residue colors follow the above-
described scheme. The short H-bond distance between the carboxylate of
Glu159 and the deacylating water (Wat) is indicated.
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enzymes. Despite this, the present structures unequivocally show
that the-loop exists in different conformations in the unbound
form (subunit D of the BEL-1 monoclinic form, in which the
omega loop is disordered), in the citrate-bound form, or in sub-
unit D of the imipenem-bound complex (Fig. 3C). In the latter, a
Glu166-Pro167 trans-peptide bond is clearly observed.
Comparison with the class A CTX-M-15, TEM-1 GES-2,
KPC-2, SHV-1, and Toho-1 native enzymes shows that they all
have the same -loop conformation as that seen in the citrate-
bound subunits of BEL-1. Thus, it is possible that the shift between
the cis- and trans-Glu159-Pro160 peptide bond in BEL-1 can be
due either to spontaneous variability of the loop or to crystal-
packing effects and that the native conformation of the-loop is
needed to bind the noncovalent weak inhibitor citrate, whereas
the covalent inhibitors imipenem and moxalactam bind the en-
zyme independently of the conformation. The superimposition of
BEL-1 with different class A enzymes also shows that the confor-
mation of the peripheral region of the active site is affected by the
variable conformation of the loop between strand 5 and helix 9
and the ﬁrst two turns of the same helix. The initial part of helix 9
(residues 262 to 268 of BEL-1) forms a wall of the active-site cavity.
The arrangement of this loop inBEL-1 shows a remarkablematching
with the corresponding loop inGES-2, and it is also similar to PER-1,
TEM-1, and SHV-1. The corresponding residues in Toho-1 and
KPC-2 instead are shifted toward the3-4 loop (maximal displace-
ment of about 6 Å), generating a greater steric hindrance in the pe-
ripheral region of the active site, especially in Toho-1. The major
hindrance in Toho-1 and KPC-2 with respect to BEL-1 andGES-2 is
due not only to the different arrangement of this loop but also to its
amino acid composition. The presence in this site of an arginine
(Arg274) and of a histidine (His274) in Toho-1 and KPC-2, respec-
tively, narrows the active-site crevice compared to that of BEL-1 and
GES-2,whereaglycine (Gly263)andanalanine (Ala264)are found in
the corresponding positions.
Functional implications and relevance of position 162. Resi-
due 162 (BEL-1 position 155), located at the beginning of the
FIG 4 Structure-based sequence alignment of representative class A -lactamases of known three-dimensional structure (PDB codes used to generate the
structural alignment are the following: GES-5, 4GNU; CTX-M-15, 4HBT; KPC-2, 2OV5; SHV-1, 1SHV; TEM-1, 1BTL; PER-1, 1E25). The secondary-structure
elements of BEL-1 are shown above the sequences, and residues of the conserved motifs of class A -lactamases are shaded in blue (consensus numbering is
reported under the sequences). The omega-loop (magenta), bearing the catalytically relevant Glu166 residue, is also indicated.
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-loop and relatively close to catalytically relevant Glu166, seems
to determine important functional differences between the two
BEL-type variants detected so far, BEL-1 and BEL-2, which differ
by a single-residue substitution at this position (Leu162 to Phe in
BEL-2). Indeed, BEL-1 and BEL-2 show signiﬁcantly different ki-
netic parameters for the hydrolysis of-lactam substrates, with an
overall decrease of both turnover rates (kcat) and Michaelis con-
stants (Km) for BEL-2 (4). As a consequence, the production of
BEL-2 in both E. coli laboratory strains and P. aeruginosa clinical
isolates translated as a higher level of resistance to oxyimino-ceph-
alosporins, in particular ceftazidime (4). The analysis of the BEL-1
structure provides a rationale for these differences. Leu162 (in
BEL-1) is found in a hydrophobic pocket of limited dimensions,
and its side chain interacts via van derWaals contacts withMet68,
Phe72, Leu139, Leu148, and Asp179 (BEL-1 residues 60, 64, 132,
141, and 172) (Fig. 5). Its replacement with a larger Phe residue,
whose side chain is approximately 2 Å longer than that of a Leu
residue, is expected to strongly affect the position of the side
chains of neighboring residues, as well as on the orientation and
ﬂexibility of the whole -loop itself. The increased ﬂexibility of
regions deﬁning the active site could determine both an increased
enzyme activity and overall loss of stability. This is illustrated by
the fact thatmanymutations conferring ESBLproperties in class A
enzymes are associated with decreased protein stability, which
could be restored by remote substitutions, such as the so-called
suppressor Met182Thr substitution occurring in TEM-type
ESBLs (37). The study of both BEL-1 and BEL-2 conforma-
tional stability, determined following the circular dichroism sig-
nal in thermal denaturation experiments (Fig. 6), conﬁrmed the
loss of stability associated with the substitution (apparent melting
point [Tm] values were the following: BEL-1, 52.4 0.2°C; BEL-2,
48.8 0.2°C). The observed Tm values were similar to that previ-
ously measured for another class A -lactamase, TEM-1 (38). In-
terestingly, a similar decrease (3 to 4°C) of the Tm value was also
observed, with some TEM-1 variants showing ESBL activity (e.g.,
with TEM-19, carrying the Gly238Ser substitution). Although
BEL-1 is already an ESBL, the Leu162Phe substitution confers a
higher level of activity on some oxyimino cephalosporins, partic-
ularly ceftazidime. Thus, a common strategy of class A-lactama-
ses to achieve this is to accumulate substitutions that enlarge the
active site but often decrease the enzyme stability, unless a com-
pensatory suppressor mutation (e.g., Met182Thr) can be intro-
duced (39). Overall, these data indicate that the accommodation
of the larger Phe162 residue in BEL-2 destabilizes the whole en-
zyme structure. This in turn is associated with greater ﬂexibility,
allowing a better accommodation of -lactam substrates (lower
Km values), but it could negatively affect turnover rates, consider-
ing that the position of Glu166 might be signiﬁcantly altered, be-
ing unable to carry out efﬁcient deacylation of the acyl-enzyme
complex.
Concluding remarks. The crystal structure of BEL-1 shows a
conformational variability of the functionally relevant -loop,
FIG 5 Hydrophobic pocket hosting the side chain of the -loop residue
Leu155 (green sticks, Leu162) is shown.
FIG 6 Thermal unfolding transition curves of puriﬁed BEL-1 (Œ) and BEL-2 () -lactamases followed by circular dichroism.
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which is uncommon in class A -lactamases. Surprisingly, this
conformational variability is observed in the crystal structures of
the imipenem- andmoxalactam-boundBEL-1, while in the native
citrate-bound structure, this loop is observed in a conformation
similar to that of other class A -lactamase structures. The con-
formational variability also appears to be linked to the slow deacy-
lation rate observed for covalently inhibited BEL-1 (both imi-
penem and moxalactam behave as inhibitors of this enzyme), as
the open conformation of the -loop destroys the Glu166-Wat-
Asn170H-bonded triad that is needed to properly orient thewater
molecule prior to the deacylation reaction.
In addition, the presence of a disulﬁde bond between Cys69
and Cys238, as commonly found in class A carbapenemases, indi-
cates that this structural element is not responsible per se for car-
bapenemase activity in the latter, as recently discussed (40).
Finally, the structures of BEL-1 also provide a rationale to ex-
plain the drastic alteration of the activity proﬁle of BEL-2, a
Leu162Phe variant. In this variant, an alteration of the -loop
structure is very likely, allowing both better recognition of bulkier
substrates (BEL-2 has much lower Km values overall for many
-lactams) and, although turnover rates overall are lower with
BEL-2, a better catalytic efﬁciency, especially for ceftazidime.
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